Regeneron Pharmaceuticals, Inc. (REGN)
USD 564.26
(-1.6%)
USD 564.26
(-1.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 4.04 Billion USD | -14.6% |
| 2022 | 4.73 Billion USD | -47.03% |
| 2021 | 8.94 Billion USD | 150.15% |
| 2020 | 3.57 Billion USD | 61.85% |
| 2019 | 2.2 Billion USD | -12.81% |
| 2018 | 2.53 Billion USD | 21.87% |
| 2017 | 2.07 Billion USD | 56.27% |
| 2016 | 1.33 Billion USD | 6.3% |
| 2015 | 1.25 Billion USD | 49.32% |
| 2014 | 838.43 Million USD | 10.32% |
| 2013 | 760.02 Million USD | 66.05% |
| 2012 | 457.71 Million USD | 323.1% |
| 2011 | -205.15 Million USD | -110.48% |
| 2010 | -97.47 Million USD | -31.54% |
| 2009 | -74.1 Million USD | 17.51% |
| 2008 | -89.83 Million USD | 21.51% |
| 2007 | -114.45 Million USD | -6.32% |
| 2006 | -107.65 Million USD | -186.52% |
| 2005 | 124.42 Million USD | 2103.7% |
| 2004 | 5.64 Million USD | 105.65% |
| 2003 | -99.98 Million USD | 18.01% |
| 2002 | -121.95 Million USD | -42.33% |
| 2001 | -85.68 Million USD | -238.99% |
| 2000 | -25.27 Million USD | -6.2% |
| 1999 | -23.8 Million USD | -88.89% |
| 1998 | -12.6 Million USD | -68.0% |
| 1997 | -7.5 Million USD | 56.65% |
| 1996 | -17.3 Million USD | -127.63% |
| 1995 | -7.6 Million USD | 73.97% |
| 1994 | -29.2 Million USD | 24.74% |
| 1993 | -38.8 Million USD | -112.02% |
| 1992 | -18.3 Million USD | -90.63% |
| 1991 | -9.6 Million USD | -190.91% |
| 1990 | -3.3 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 1.17 Billion USD | 7.86% |
| 2024 Q1 | 758.5 Million USD | -22.04% |
| 2024 Q2 | 1.09 Billion USD | 44.17% |
| 2023 Q3 | 1.11 Billion USD | 9.3% |
| 2023 Q4 | 972.9 Million USD | -12.43% |
| 2023 FY | 4.04 Billion USD | -14.6% |
| 2023 Q1 | 946.7 Million USD | -17.45% |
| 2023 Q2 | 1.01 Billion USD | 7.37% |
| 2022 Q2 | 1.1 Billion USD | -11.81% |
| 2022 Q4 | 1.14 Billion USD | -6.28% |
| 2022 FY | 4.73 Billion USD | -47.03% |
| 2022 Q1 | 1.25 Billion USD | -52.32% |
| 2022 Q3 | 1.22 Billion USD | 10.25% |
| 2021 FY | 8.94 Billion USD | 150.15% |
| 2021 Q2 | 3.34 Billion USD | 200.82% |
| 2021 Q1 | 1.11 Billion USD | -4.65% |
| 2021 Q4 | 2.63 Billion USD | 42.9% |
| 2021 Q3 | 1.84 Billion USD | -44.81% |
| 2020 FY | 3.57 Billion USD | 61.85% |
| 2020 Q4 | 1.16 Billion USD | 10.82% |
| 2020 Q3 | 1.05 Billion USD | 60.44% |
| 2020 Q2 | 656.4 Million USD | -6.24% |
| 2020 Q1 | 700.1 Million USD | 3.61% |
| 2019 Q4 | 675.7 Million USD | -8.5% |
| 2019 FY | 2.2 Billion USD | -12.81% |
| 2019 Q1 | 480 Million USD | -33.16% |
| 2019 Q2 | 315.6 Million USD | -34.25% |
| 2019 Q3 | 738.5 Million USD | 134.0% |
| 2018 Q3 | 626.92 Million USD | 0.76% |
| 2018 Q2 | 622.18 Million USD | 9.69% |
| 2018 Q1 | 567.23 Million USD | 5.27% |
| 2018 FY | 2.53 Billion USD | 21.87% |
| 2018 Q4 | 718.1 Million USD | 14.54% |
| 2017 Q3 | 559.92 Million USD | 1.75% |
| 2017 FY | 2.07 Billion USD | 56.27% |
| 2017 Q4 | 538.81 Million USD | -3.77% |
| 2017 Q1 | 430.54 Million USD | 24.07% |
| 2017 Q2 | 550.31 Million USD | 27.82% |
| 2016 Q2 | 291.62 Million USD | -11.44% |
| 2016 Q3 | 362.8 Million USD | 24.41% |
| 2016 FY | 1.33 Billion USD | 6.3% |
| 2016 Q1 | 329.3 Million USD | 42.51% |
| 2016 Q4 | 347 Million USD | -4.35% |
| 2015 Q3 | 392.42 Million USD | 13.79% |
| 2015 FY | 1.25 Billion USD | 49.32% |
| 2015 Q2 | 344.85 Million USD | 21.62% |
| 2015 Q4 | 231.08 Million USD | -41.11% |
| 2015 Q1 | 283.55 Million USD | 14.63% |
| 2014 FY | 838.43 Million USD | 10.32% |
| 2014 Q3 | 182.71 Million USD | -17.84% |
| 2014 Q2 | 222.4 Million USD | 19.61% |
| 2014 Q1 | 185.93 Million USD | -12.32% |
| 2014 Q4 | 247.36 Million USD | 35.38% |
| 2013 Q2 | 158.1 Million USD | 3.3% |
| 2013 Q3 | 236.8 Million USD | 49.78% |
| 2013 FY | 760.02 Million USD | 66.05% |
| 2013 Q4 | 212.07 Million USD | -10.44% |
| 2013 Q1 | 153.05 Million USD | 5.07% |
| 2012 FY | 457.71 Million USD | 323.1% |
| 2012 Q1 | 22.2 Million USD | 148.9% |
| 2012 Q2 | 87.47 Million USD | 294.03% |
| 2012 Q3 | 202.36 Million USD | 131.33% |
| 2012 Q4 | 145.67 Million USD | -28.02% |
| 2011 Q1 | -40.98 Million USD | -220.74% |
| 2011 FY | -205.15 Million USD | -110.48% |
| 2011 Q4 | -45.4 Million USD | 22.33% |
| 2011 Q3 | -58.45 Million USD | 3.09% |
| 2011 Q2 | -60.31 Million USD | -47.19% |
| 2010 Q3 | -32.09 Million USD | -35.28% |
| 2010 Q4 | -12.77 Million USD | 60.19% |
| 2010 FY | -97.47 Million USD | -31.54% |
| 2010 Q1 | -28.65 Million USD | 27.28% |
| 2010 Q2 | -23.72 Million USD | 17.22% |
| 2009 Q1 | -19.23 Million USD | 44.42% |
| 2009 Q2 | -16.26 Million USD | 15.42% |
| 2009 Q3 | -1.29 Million USD | 92.06% |
| 2009 Q4 | -39.4 Million USD | -2952.52% |
| 2009 FY | -74.1 Million USD | 17.51% |
| 2008 Q3 | -19.93 Million USD | -2.8% |
| 2008 Q4 | -34.59 Million USD | -73.59% |
| 2008 FY | -89.83 Million USD | 21.51% |
| 2008 Q1 | -15.91 Million USD | -37.95% |
| 2008 Q2 | -19.38 Million USD | -21.86% |
| 2007 FY | -114.45 Million USD | -6.32% |
| 2007 Q4 | -11.53 Million USD | 70.17% |
| 2007 Q3 | -38.66 Million USD | -26.35% |
| 2007 Q2 | -30.6 Million USD | 9.05% |
| 2007 Q1 | -33.64 Million USD | -0.49% |
| 2006 Q3 | -28.25 Million USD | -16.53% |
| 2006 Q2 | -24.24 Million USD | -11.94% |
| 2006 Q1 | -21.66 Million USD | -109.88% |
| 2006 FY | -107.65 Million USD | -186.52% |
| 2006 Q4 | -33.48 Million USD | -18.51% |
| 2005 Q3 | -34.38 Million USD | -6.9% |
| 2005 Q1 | -28.34 Million USD | -813.14% |
| 2005 Q2 | -32.16 Million USD | -13.5% |
| 2005 FY | 124.42 Million USD | 2103.7% |
| 2005 Q4 | 219.31 Million USD | 737.78% |
| 2004 Q3 | -9.47 Million USD | 25.03% |
| 2004 FY | 5.64 Million USD | 105.65% |
| 2004 Q1 | 23.79 Million USD | 238.83% |
| 2004 Q2 | -12.64 Million USD | -153.14% |
| 2004 Q4 | 3.97 Million USD | 141.92% |
| 2003 Q1 | -28.37 Million USD | 18.06% |
| 2003 FY | -99.98 Million USD | 18.01% |
| 2003 Q4 | -17.13 Million USD | 33.32% |
| 2003 Q3 | -25.7 Million USD | 4.56% |
| 2003 Q2 | -26.93 Million USD | 5.1% |
| 2002 Q1 | -25.19 Million USD | 14.87% |
| 2002 FY | -121.95 Million USD | -42.33% |
| 2002 Q2 | -29.95 Million USD | -18.88% |
| 2002 Q3 | -32.17 Million USD | -7.43% |
| 2002 Q4 | -34.63 Million USD | -7.64% |
| 2001 Q2 | -18.08 Million USD | -51.48% |
| 2001 FY | -85.68 Million USD | -238.99% |
| 2001 Q4 | -29.59 Million USD | -27.04% |
| 2001 Q3 | -23.29 Million USD | -28.8% |
| 2001 Q1 | -11.93 Million USD | -25.54% |
| 2000 FY | -25.27 Million USD | -6.2% |
| 2000 Q1 | -8.48 Million USD | -1111.43% |
| 2000 Q2 | -3.97 Million USD | 53.13% |
| 2000 Q3 | -4.58 Million USD | -15.27% |
| 2000 Q4 | -9.51 Million USD | -107.55% |
| 1999 Q3 | -5.1 Million USD | 39.29% |
| 1999 Q4 | -700 Thousand USD | 86.27% |
| 1999 FY | -23.8 Million USD | -88.89% |
| 1999 Q1 | -9.3 Million USD | -50.0% |
| 1999 Q2 | -8.4 Million USD | 9.68% |
| 1998 Q3 | -2.4 Million USD | -442.86% |
| 1998 Q4 | -6.2 Million USD | -158.33% |
| 1998 FY | -12.6 Million USD | -68.0% |
| 1998 Q1 | -4.9 Million USD | -508.33% |
| 1998 Q2 | 700 Thousand USD | 114.29% |
| 1997 Q2 | -3.7 Million USD | 9.76% |
| 1997 FY | -7.5 Million USD | 56.65% |
| 1997 Q4 | 1.2 Million USD | 209.09% |
| 1997 Q3 | -1.1 Million USD | 70.27% |
| 1997 Q1 | -4.1 Million USD | 8.89% |
| 1996 FY | -17.3 Million USD | -127.63% |
| 1996 Q4 | -4.5 Million USD | -2.27% |
| 1996 Q3 | -4.4 Million USD | -18.92% |
| 1996 Q2 | -3.7 Million USD | 21.28% |
| 1996 Q1 | -4.7 Million USD | -74.07% |
| 1995 Q3 | -2.4 Million USD | -84.62% |
| 1995 Q4 | -2.7 Million USD | -12.5% |
| 1995 Q2 | -1.3 Million USD | 38.1% |
| 1995 Q1 | -2.1 Million USD | 58.82% |
| 1995 FY | -7.6 Million USD | 73.97% |
| 1994 Q4 | -5.1 Million USD | -37.84% |
| 1994 FY | -29.2 Million USD | 24.74% |
| 1994 Q1 | -10.4 Million USD | 7.14% |
| 1994 Q2 | -10 Million USD | 3.85% |
| 1994 Q3 | -3.7 Million USD | 63.0% |
| 1993 Q3 | -9.3 Million USD | 5.1% |
| 1993 Q2 | -9.8 Million USD | -6.52% |
| 1993 FY | -38.8 Million USD | -112.02% |
| 1993 Q1 | -9.2 Million USD | -50.82% |
| 1993 Q4 | -11.2 Million USD | -20.43% |
| 1992 Q1 | -3.2 Million USD | 13.51% |
| 1992 Q2 | -3.5 Million USD | -9.38% |
| 1992 Q3 | -5.6 Million USD | -60.0% |
| 1992 Q4 | -6.1 Million USD | -8.93% |
| 1992 FY | -18.3 Million USD | -90.63% |
| 1991 FY | -9.6 Million USD | -190.91% |
| 1991 Q4 | -3.7 Million USD | -48.0% |
| 1991 Q1 | 2 Million USD | 128.57% |
| 1991 Q3 | -2.5 Million USD | -25.0% |
| 1991 Q2 | -2 Million USD | -200.0% |
| 1990 Q3 | 1.3 Million USD | 8.33% |
| 1990 Q2 | 1.2 Million USD | 0.0% |
| 1990 Q1 | 1.2 Million USD | 0.0% |
| 1990 Q4 | -7 Million USD | -638.46% |
| 1990 FY | -3.3 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 1806.147% |
| Alkermes plc | 414.12 Million USD | -877.272% |
| Agenus Inc. | -159.54 Million USD | 2636.588% |
| Aptorum Group Limited | -10.52 Million USD | 38558.359% |
| Ardelyx, Inc. | -63.27 Million USD | 6495.948% |
| Dyadic International, Inc. | -8.22 Million USD | 49276.529% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | 339621.812% |
| Lantern Pharma Inc. | -17.87 Million USD | 22737.864% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 20245.057% |
| Novavax, Inc. | -566.51 Million USD | 814.39% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 5645.568% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 5023.719% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 20941.448% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 38413.926% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 7717.872% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 1163.638% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 16750.205% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 10787.106% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 3237.579% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 4922.914% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 23174.862% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 9295.865% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 16390.05% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 3010.934% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 1534.252% |
| AlloVir, Inc. | -181.33 Million USD | 2331.885% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 2074.176% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 13932.456% |
| Bicycle Therapeutics plc | -189.94 Million USD | 2230.658% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 2455.951% |
| ChromaDex Corporation | -5.59 Million USD | 72382.55% |
| Chimerix, Inc. | -93.06 Million USD | 4448.681% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 9078.133% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 3587.106% |
| CRISPR Therapeutics AG | -222.53 Million USD | 1918.611% |
| Precision BioSciences, Inc. | -43.73 Million USD | 9353.475% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 2224.339% |
| Fortress Biotech, Inc. | -142.34 Million USD | 2943.223% |
| Fortress Biotech, Inc. | -142.34 Million USD | 2943.223% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 4242.629% |
| ImmuCell Corporation | -5.74 Million USD | 70507.882% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 3110.586% |
| Immix Biopharma, Inc. | -16.14 Million USD | 25173.24% |
| Incyte Corporation | 620.52 Million USD | -552.206% |
| Innoviva, Inc. | 176.7 Million USD | -2190.263% |
| IO Biotech, Inc. | -91.44 Million USD | 4525.817% |
| Jaguar Health, Inc. | -34.29 Million USD | 11902.222% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 2481.474% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | -33789.633% |
| ContextLogic Inc. | -328 Million USD | 1333.872% |
| MiMedx Group, Inc. | 37.11 Million USD | -10803.923% |
| MEI Pharma, Inc. | 14.54 Million USD | -27730.422% |
| NextCure, Inc. | -67.63 Million USD | 6083.559% |
| Onconetix, Inc. | -36.03 Million USD | 11331.152% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 9802.019% |
| Opthea Limited | -191.84 Million USD | 2209.593% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 147169.672% |
| Vaxcyte, Inc. | -468.04 Million USD | 964.689% |
| PDS Biotechnology Corporation | -43.04 Million USD | 9501.97% |
| Precigen, Inc. | -88.92 Million USD | 4651.241% |
| Pharming Group N.V. | -4.87 Million USD | 83040.127% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 2518.894% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 13700.954% |
| PureTech Health plc | -146.19 Million USD | 2868.213% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 19850.622% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 1817.799% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 16750.205% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 1577.017% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 13910.271% |
| Acelyrin, Inc. | -422.06 Million USD | 1058.883% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | 31385278.993% |
| Summit Therapeutics Inc. | -89.73 Million USD | 4610.007% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 11019.221% |
| Senti Biosciences, Inc. | -92.72 Million USD | 4464.532% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 3626.178% |
| Elevation Oncology, Inc. | -45.44 Million USD | 9005.49% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 11910.488% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 102764.909% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | 128091.777% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 12356.14% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 47707.34% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 6051.968% |
| Seer, Inc. | -103.46 Million USD | 4011.64% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 6254.443% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 5726.208% |
| ESSA Pharma Inc. | -32.13 Million USD | 12694.407% |
| GlycoMimetics, Inc. | -39.27 Million USD | 10404.443% |
| GT Biopharma, Inc. | -13.57 Million USD | 29910.695% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 1946.128% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 8849.351% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -4561.913% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 7230.323% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 7957.531% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 40824.94% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 902.494% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 58770.629% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 8083.548% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 1658.621% |
| Aptose Biosciences Inc. | -52.35 Million USD | 7829.964% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 28164.374% |
| Soligenix, Inc. | -7.69 Million USD | 52673.805% |
| Century Therapeutics, Inc. | -146.54 Million USD | 2861.658% |
| Kura Oncology, Inc. | -165.8 Million USD | 2540.894% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 4430.394% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 48748.876% |
| Ocean Biomedical, Inc. | -2.48 Million USD | 163181.738% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 62516.718% |
| Autolus Therapeutics plc | -195.02 Million USD | 2175.138% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 4880.585% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 5594.149% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 19248.805% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 1882.589% |
| GRI Bio, Inc. | -11.38 Million USD | 35641.407% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 89722.574% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 3184.844% |
| IGM Biosciences, Inc. | -263.46 Million USD | 1636.129% |
| INmune Bio, Inc. | -29.74 Million USD | 13707.814% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 3758.726% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 10729.195% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 25427.045% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 25761.939% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 6723.948% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 3863.974% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 1566.309% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 2091.693% |
| Verastem, Inc. | -92.08 Million USD | 4495.009% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 8686.189% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 2297.779% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 3518.736% |
| Histogen Inc. | -10.64 Million USD | 38125.933% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 26257.643% |
| Surrozen, Inc. | -45.78 Million USD | 8940.323% |
| Organovo Holdings, Inc. | -15.08 Million USD | 26926.859% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 79607.119% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 6926.923% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 7990.007% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 16109.098% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 53122.183% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 2462.815% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 8453.5% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 5274.989% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 26689.318% |
| Apollomics, Inc. | -54.83 Million USD | 7480.64% |
| Amarin Corporation plc | -67.58 Million USD | 6087.897% |
| Mesoblast Limited | -58.79 Million USD | 6983.526% |
| Turnstone Biologics Corp. | -59.03 Million USD | 6955.773% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 2544.934% |
| Synaptogenix, Inc. | -8.31 Million USD | 48778.988% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 27846.469% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 4513.847% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 84564.755% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 45927.113% |
| Exelixis, Inc. | 170.88 Million USD | -2268.318% |
| Better Therapeutics, Inc. | -38.26 Million USD | 10677.335% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 2709.971% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 882.621% |
| NLS Pharmaceutics AG | -11.8 Million USD | 34376.941% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 50425.134% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 13593.482% |
| Gritstone bio, Inc. | -154.63 Million USD | 2717.212% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 5977.202% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 23735.389% |
| Avid Bioservices, Inc. | -18.67 Million USD | 21767.737% |
| Insmed Incorporated | -709.62 Million USD | 670.315% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 25894.485% |
| MediWound Ltd. | -15.29 Million USD | 26568.934% |
| OmniAb, Inc. | -69.41 Million USD | 5929.96% |
| Alector, Inc. | -151.74 Million USD | 2767.128% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 3847.905% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 7860.796% |
| Zai Lab Limited | -366.57 Million USD | 1204.037% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 1377.586% |
| Aura Biosciences, Inc. | -84.99 Million USD | 4861.798% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 1748.52% |
| Immunic, Inc. | -99.22 Million USD | 4178.792% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 2927.016% |
| Veracyte, Inc. | -85.79 Million USD | 4817.175% |
| InMed Pharmaceuticals Inc. | - USD | -Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 1536.084% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 28580.647% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 58856.259% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 21635.585% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | -599.488% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 16000.287% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | -10330.132% |
| TG Therapeutics, Inc. | 20.63 Million USD | -19514.695% |
| Galecto, Inc. | -39.9 Million USD | 10241.837% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 9719.005% |
| Fortrea Holdings Inc. | 63.1 Million USD | -6313.788% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 2981.626% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 14114.475% |
| XBiotech Inc. | -37.51 Million USD | 10889.389% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 5977.202% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 6129.648% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 3850.579% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 15864.646% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 7694.198% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 811.005% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 5256.067% |
| Vaxxinity, Inc. | -58.28 Million USD | 7043.639% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 4002.361% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 18286.653% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 4783.276% |
| NexImmune, Inc. | -29.19 Million USD | 13963.502% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | 72110.764% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 27855.264% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 15996.54% |
| Scopus BioPharma Inc. | -11.71 Million USD | 34646.671% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 3285.138% |
| Ainos, Inc. | -13.2 Million USD | 30745.0% |
| Pluri Inc. | -22.15 Million USD | 18364.735% |
| Prothena Corporation plc | -191.03 Million USD | 2218.501% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 3031.874% |
| Celularity Inc. | -192.28 Million USD | 2204.718% |
| Rallybio Corporation | -78.93 Million USD | 5227.325% |
| Cue Biopharma, Inc. | -52.14 Million USD | 7860.647% |
| MeiraGTx Holdings plc | -137.06 Million USD | 3052.773% |
| Omeros Corporation | -164.53 Million USD | 2559.795% |
| Humacyte, Inc. | -100.04 Million USD | 4145.199% |
| Immunocore Holdings plc | -59.64 Million USD | 6884.858% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 21906.671% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 16630.245% |
| Blueprint Medicines Corporation | -486.27 Million USD | 932.262% |
| CalciMedica, Inc. | -21.87 Million USD | 18601.029% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 5520.707% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 3177.994% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 2462.649% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 1338.024% |
| Pulmatrix, Inc. | -14.74 Million USD | 27556.581% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 11422.143% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 4654.16% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 885.401% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 6091.177% |
| Cytokinetics, Incorporated | -496.2 Million USD | 915.61% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 11858.331% |
| Nutriband Inc. | -4.87 Million USD | 83169.817% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 9379.573% |
| Vor Biopharma Inc. | -126.03 Million USD | 3311.067% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 4.595% |
| Evogene Ltd. | -26.39 Million USD | 15435.152% |
| ProKidney Corp. | -151.52 Million USD | 2770.965% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 6371.171% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 52712.749% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 766.332% |
| CorMedix Inc. | -48.95 Million USD | 8366.509% |
| BioLineRx Ltd. | -49.69 Million USD | 8244.042% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 3644.708% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 10730.122% |
| Atai Life Sciences N.V. | -125.47 Million USD | 3325.526% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 5057.294% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 5071.318% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 1725.42% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 13265.582% |
| MediciNova, Inc. | -9.9 Million USD | 40978.704% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 3302.504% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 55980.192% |
| GeoVax Labs, Inc. | -26.74 Million USD | 15233.34% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 1845.756% |
| Biomea Fusion, Inc. | -126.13 Million USD | 3308.546% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 1258.293% |
| Mereo BioPharma Group plc | -28.41 Million USD | 14342.328% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 2217.914% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 1859.961% |
| Absci Corporation | -115.51 Million USD | 3603.528% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 14770.316% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 3685.725% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 1771.237% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 16162.47% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 2045.777% |
| Allakos Inc. | -196.05 Million USD | 2164.257% |
| Imunon, Inc. | -21.03 Million USD | 19344.019% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 3757.106% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | -3672.394% |
| BioAtla, Inc. | -129.68 Million USD | 3220.667% |
| NLS Pharmaceutics AG | -11.8 Million USD | 34376.941% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 25645.036% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 1334.862% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 9791.796% |
| XOMA Corporation | -41.84 Million USD | 9770.952% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 3945.701% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 3431.084% |
| aTyr Pharma, Inc. | -54.91 Million USD | 7469.216% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 4729.119% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 2441.123% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 1690.529% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 18953.536% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 49378.226% |
| Akari Therapeutics, Plc | -16.8 Million USD | 24181.28% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 45766087.45% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | -1098.878% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 62038.879% |
| UroGen Pharma Ltd. | -65.53 Million USD | 6275.385% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 4633.144% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 55822.061% |
| Orgenesis Inc. | -53.63 Million USD | 7645.492% |
| Entera Bio Ltd. | -8.89 Million USD | 45619.064% |
| GH Research PLC | -41.22 Million USD | 9917.816% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 15842.57% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 4972.912% |
| Xencor, Inc. | -138.63 Million USD | 3019.164% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | 78614.596% |
| Replimune Group, Inc. | -234.77 Million USD | 1823.835% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 18931.499% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 29107.311% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 62038.879% |
| Portage Biotech Inc. | -18.25 Million USD | 22272.246% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 55980.192% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 3955.813% |
| OncoCyte Corporation | -25.13 Million USD | 16200.812% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 35899.657% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 35424.068% |
| Purple Biotech Ltd. | 22.27 Million USD | -18072.062% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 53975.133% |
| scPharmaceuticals Inc. | -55.39 Million USD | 7405.762% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 21515.842% |
| HilleVax, Inc. | -133.34 Million USD | 3135.059% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 33688.68% |
| Tharimmune, Inc. | -9.45 Million USD | 42902.812% |
| Genprex, Inc. | -31.07 Million USD | 13123.414% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 2250.494% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 12998.301% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | 529132.68% |
| Virios Therapeutics, Inc. | -5.44 Million USD | 74400.719% |
| OKYO Pharma Limited | -15.74 Thousand USD | 25696413.524% |
| Savara Inc. | -60 Million USD | 6844.38% |
| Curis, Inc. | -48.33 Million USD | 8473.541% |
| Daré Bioscience, Inc. | -30.83 Million USD | 13222.943% |
| Carmell Therapeutics Corporation | -5.21 Million USD | 77671.072% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 55714.951% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 14951.743% |
| BeiGene, Ltd. | -1.2 Billion USD | 435.098% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 20397.102% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 930.711% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 4421.424% |
| Erasca, Inc. | -141.52 Million USD | 2959.636% |
| bluebird bio, Inc. | -244.26 Million USD | 1756.868% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 89499.674% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | -1981.403% |
| DBV Technologies S.A. | -76.43 Million USD | 5395.033% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | 89499.674% |
| Moderna, Inc. | -4.23 Billion USD | 195.473% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 9598.228% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 63733.648% |
| Molecular Templates, Inc. | -10.46 Million USD | 38769.024% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 6119.156% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 1174.231% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 2923.998% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 7883.932% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 2718.77% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 2044.506% |
| MacroGenics, Inc. | -168.24 Million USD | 2505.494% |
| RenovoRx, Inc. | -11.39 Million USD | 35613.338% |
| Adicet Bio, Inc. | -152.03 Million USD | 2761.9% |
| Prime Medicine, Inc. | -191.29 Million USD | 2215.666% |
| Aditxt, Inc. | -26.06 Million USD | 15628.486% |
| Adagene Inc. | -23.71 Million USD | 17162.069% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 55463.143% |
| Quantum-Si incorporated | -111.17 Million USD | 3740.428% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 12887.854% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 27862.138% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | -3216.914% |
| SciSparc Ltd. | -5.77 Million USD | 70203.932% |
| Vericel Corporation | -6.46 Million USD | 62709.839% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 46851.266% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 17605.079% |
| Generation Bio Co. | -138.56 Million USD | 3020.765% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 4974.262% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 4780.893% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 1778.591% |
| Invivyd, Inc. | -207.78 Million USD | 2047.753% |
| Relay Therapeutics, Inc. | -373 Million USD | 1185.013% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 43252.938% |
| Spero Therapeutics, Inc. | 21.48 Million USD | -18740.371% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 39441.888% |
| 2seventy bio, Inc. | -216.7 Million USD | 1967.579% |
| ADMA Biologics, Inc. | 21.63 Million USD | -18608.857% |
| Clene Inc. | -40.54 Million USD | 10082.98% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 16908.388% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 7485.758% |
| GeoVax Labs, Inc. | -26.74 Million USD | 15233.34% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 1256.116% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 11117.908% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | -25073.229% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 4002.625% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 12002.535% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 2476.76% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 691.418% |
| Evaxion Biotech A/S | -22.19 Million USD | 18332.644% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 5012.602% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 1913.834% |
| Trevena, Inc. | -35.28 Million USD | 11568.771% |
| Surrozen, Inc. | -45.78 Million USD | 8940.323% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 5162.355% |
| Cingulate Inc. | -22.75 Million USD | 17882.267% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | -53918.954% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 9160.604% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 49251.433% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 4046.157% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 5615.338% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 6619.799% |
| Clearmind Medicine Inc. | -8.74 Million USD | 46398.34% |
| Kronos Bio, Inc. | -121.83 Million USD | 3421.924% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 5411.434% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 138085.704% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 4113.905% |
| Statera Biopharma, Inc. | -98.34 Million USD | 4215.257% |
| ImmunityBio, Inc. | -362.25 Million USD | 1217.212% |
| Korro Bio, Inc. | -84.53 Million USD | 4887.541% |
| Kineta, Inc. | -15.72 Million USD | 25839.999% |
| BioVie Inc. | -32.17 Million USD | 12676.607% |
| Codexis, Inc. | -68.06 Million USD | 6045.585% |
| Celularity Inc. | -192.28 Million USD | 2204.718% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 1918.039% |
| Celcuity Inc. | -66.23 Million USD | 6210.644% |
| Virax Biolabs Group Limited | -6.49 Million USD | 62396.88% |
| Cibus, Inc. | -318.88 Million USD | 1369.149% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 9511.86% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 12058.102% |
| IN8bio, Inc. | -30.33 Million USD | 13440.475% |
| Kodiak Sciences Inc. | -277.32 Million USD | 1559.356% |
| Annexon, Inc. | -143.72 Million USD | 2915.903% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 3369.301% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 6360.403% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 17362.839% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 1244.121% |
| Eyenovia, Inc. | -25.4 Million USD | 16029.422% |
| Puma Biotechnology, Inc. | 32.64 Million USD | -12299.203% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 72863.394% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 5214.301% |
| Arcellx, Inc. | -89.88 Million USD | 4602.781% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 9011.962% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 3049.631% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 13109.418% |
| Moolec Science SA | -6.65 Million USD | 60923.844% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 6719.615% |
| Geron Corporation | -193.94 Million USD | 2186.736% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 9456.808% |
| Royalty Pharma plc | 1.49 Billion USD | -171.226% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 2565.309% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 43487.201% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 18584.414% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 2467.32% |
| Humacyte, Inc. | -100.04 Million USD | 4145.199% |
| Structure Therapeutics Inc. | -102.77 Million USD | 4037.825% |
| 89bio, Inc. | -151.2 Million USD | 2776.583% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 5150.542% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 27934.25% |
| Genelux Corporation | -24.16 Million USD | 16847.776% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 12030.254% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 2456.39% |
| Notable Labs, Ltd. | -14.65 Million USD | 27712.062% |
| Liquidia Corporation | -73.38 Million USD | 5614.962% |
| Mustang Bio, Inc. | -50.72 Million USD | 8078.354% |
| Immunovant, Inc. | -282.7 Million USD | 1531.543% |
| Quantum-Si incorporated | -111.17 Million USD | 3740.428% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 5281.747% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 19129.953% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 4067.278% |
| Acasti Pharma Inc. | -11.31 Million USD | 35877.051% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 17756.653% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 25427.045% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 1990.691% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | 110403.096% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 25575.891% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 13980.372% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 9879.383% |
| PepGen Inc. | -84.76 Million USD | 4874.438% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 13758.331% |
| United Therapeutics Corporation | 1.18 Billion USD | -241.556% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 17775.241% |
| Solid Biosciences Inc. | -104.31 Million USD | 3979.691% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 12435.667% |
| Immuneering Corporation | -58.41 Million USD | 7028.437% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | 79607.119% |
| Silo Pharma, Inc. | -3.85 Million USD | 105067.019% |
| Belite Bio, Inc | -31.66 Million USD | 12879.778% |
| XOMA Corporation | -41.84 Million USD | 9770.952% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 6093.928% |
| Bionomics Limited | -17.89 Billion USD | 122.619% |
| Apogee Therapeutics, Inc. | -93 Million USD | 4451.58% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -11242.769% |
| uniQure N.V. | -282.87 Million USD | 1530.723% |
| Cassava Sciences, Inc. | -105.95 Million USD | 3919.568% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 55463.143% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 3225.077% |
| Forte Biosciences, Inc. | -32.48 Million USD | 12557.982% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 48808.862% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 13867.988% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | 72863.394% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 28580.647% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 45629.306% |
| Altimmune, Inc. | -95.92 Million USD | 4318.849% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 5606.708% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | -11242.769% |
| Compugen Ltd. | -12.99 Million USD | 31250.708% |
| Peak Bio, Inc. | -1356.23 USD | 298408187.124% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 8258.818% |
| Benitec Biopharma Inc. | -22.49 Million USD | 18095.109% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 1770.264% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 13705.527% |
| Zura Bio Limited | -62.63 Million USD | 6561.094% |
| PolyPid Ltd. | -22.86 Million USD | 17798.43% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 24965.446% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 13705.527% |
| Instil Bio, Inc. | -159.16 Million USD | 2642.643% |
| argenx SE | -425.04 Million USD | 1052.149% |
| Immunome, Inc. | -109.53 Million USD | 3794.969% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 8135.86% |
| Verona Pharma plc | -67.83 Million USD | 6066.455% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 15629.931% |
| Shattuck Labs, Inc. | -91.95 Million USD | 4501.079% |
| CervoMed Inc. | -7.81 Million USD | 51900.261% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 5635.631% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 30481.353% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 8501.005% |
| Moolec Science SA | -6.65 Million USD | 60923.844% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 24704.765% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 3092.827% |
| AnaptysBio, Inc. | -164.41 Million USD | 2561.575% |
| Design Therapeutics, Inc. | -78.19 Million USD | 5275.982% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 4749.648% |
| NeurAxis, Inc. | -6.66 Million USD | 60826.282% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 10093.086% |
| Lumos Pharma, Inc. | -36.61 Million USD | 11153.422% |
| Achilles Therapeutics plc | -75.25 Million USD | 5477.849% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 15629.931% |
| 180 Life Sciences Corp. | -13.47 Million USD | 30128.566% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | -78388.284% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | 138085.704% |
| Nutriband Inc. | -4.87 Million USD | 83169.817% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 3753.277% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 7398.779% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 8061.091% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 6222.786% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 7577.584% |
| Palisade Bio, Inc. | -13.07 Million USD | 31064.805% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 9012.55% |
| Beam Therapeutics Inc. | -176.48 Million USD | 2393.169% |
| Neurogene Inc. | -55.58 Million USD | 7381.183% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 3807.697% |
| AEON Biopharma, Inc. | -48.42 Million USD | 8456.77% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 4284.779% |
| Sesen Bio, Inc. | -25.9 Million USD | 15720.441% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 4945.144% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 32253.281% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 978.736% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 5686.908% |
| Athira Pharma, Inc. | -125.46 Million USD | 3325.655% |
| Vaccinex, Inc. | -22.88 Million USD | 17784.51% |
| HCW Biologics Inc. | -25.71 Million USD | 15836.963% |
| XOMA Corporation | -41.84 Million USD | 9770.952% |
| Nektar Therapeutics | -137.42 Million USD | 3044.952% |
| Arvinas, Inc. | -401.5 Million USD | 1107.995% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | 45766087.45% |
| Merus N.V. | -156.54 Million USD | 2685.23% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 4136.565% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 11790.064% |
| Rezolute, Inc. | -70.42 Million USD | 5846.844% |
| Clene Inc. | -40.54 Million USD | 10082.98% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 24809.872% |
| BeyondSpring Inc. | -23.11 Million USD | 17609.302% |
| Synlogic, Inc. | -55.16 Million USD | 7436.887% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 22672.927% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 37490.059% |
| Peak Bio, Inc. | -1356.23 USD | 298408187.124% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 10092.099% |
| Krystal Biotech, Inc. | -109.72 Million USD | 3788.336% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 3224.209% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 1279.868% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | 85374.759% |
| MannKind Corporation | 8.67 Million USD | -46536.322% |
| Ikena Oncology, Inc. | -75.41 Million USD | 5466.297% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 42051.902% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 6119.783% |
| Gossamer Bio, Inc. | -183.75 Million USD | 2302.396% |
| CohBar, Inc. | -12.38 Million USD | 32768.736% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 8078.669% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 14770.316% |
| Legend Biotech Corporation | -439.48 Million USD | 1020.873% |
| Mural Oncology plc | -194.63 Million USD | 2179.296% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 6127.583% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 25166.784% |
| Disc Medicine, Inc. | -91.12 Million USD | 4541.262% |
| Champions Oncology, Inc. | -7.35 Million USD | 55117.673% |
| REGENXBIO Inc. | -268.12 Million USD | 1609.391% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 37859.184% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 7358.591% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 10487.662% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 3639.005% |
| Vaxart, Inc. | -83.34 Million USD | 4955.724% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 47601.129% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 9557.149% |
| Cellectis S.A. | -106.62 Million USD | 3895.603% |
| Longeveron Inc. | -21.02 Million USD | 19345.328% |
| Repare Therapeutics Inc. | -116.22 Million USD | 3582.155% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 1611.104% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 5450.122% |
| Revolution Medicines, Inc. | -487.18 Million USD | 930.711% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 60940.349% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 9307.581% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 5525.794% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 5911.876% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 36855.063% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 6.045% |
| Denali Therapeutics Inc. | -196.69 Million USD | 2157.509% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 46851.266% |
| Veru Inc. | -93.78 Million USD | 4415.424% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 17447.936% |
| Cingulate Inc. | -22.75 Million USD | 17882.267% |
| Passage Bio, Inc. | -108.38 Million USD | 3833.866% |
| Context Therapeutics Inc. | -25.07 Million USD | 16241.515% |
| Exicure, Inc. | -14.99 Million USD | 27087.863% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 2064.001% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 10068.718% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 41749.956% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 2295.252% |
| Nuvalent, Inc. | -149.49 Million USD | 2807.235% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 49355.712% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 4661.089% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 19581.563% |
| OmniAb, Inc. | -69.41 Million USD | 5929.96% |
| Anew Medical, Inc. | -1.3 Million USD | 311214.357% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 31789.766% |
| Lipocine Inc. | -17.93 Million USD | 22670.463% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 6007.054% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 5414.503% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 10729.195% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 10338.824% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 18180.325% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 797.958% |
| Ocugen, Inc. | -65.53 Million USD | 6275.856% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 4411.572% |
| Q32 Bio Inc. | -92.1 Million USD | 4494.15% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 18977.28% |
| Alumis Inc. Common Stock | -158.17 Million USD | 2658.638% |
| Equillium, Inc. | -14.52 Million USD | 27968.751% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 6585.114% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 51307.406% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 21552.832% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 8719.838% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 3831.215% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 33910.317% |
| Dominari Holdings Inc. | -21.79 Million USD | 18668.086% |
| Edesa Biotech, Inc. | -9.22 Million USD | 43981.668% |
| vTv Therapeutics Inc. | -25.5 Million USD | 15969.736% |
| Bio-Techne Corporation | 206.68 Million USD | -1858.091% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 1133.776% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | -2007.535% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 3159.564% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 10641.794% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 2778.407% |
| Nkarta, Inc. | -131.65 Million USD | 3174.136% |
| BioCardia, Inc. | -11.64 Million USD | 34856.956% |
| Iterum Therapeutics plc | -47.46 Million USD | 8625.954% |